Drug profile

The FDA adverse-event record for Dorzolamide Hcl

11 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Dorzolamide Hcl. See the species affected, top reactions, and outcomes below.

11
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
3
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
11
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Dorzolamide Hcl

Administration Routes

UnknownOphthalmicIntraocular

Species Affected

Dog 10
Cat 1

Most Affected Breeds

Pinscher - Miniature 1
Terrier - Jack Russell 1
Terrier - Boston 1
Spaniel - Cocker American 1
Beagle 1
Shih Tzu 1
Retriever - Labrador 1
Spaniel (unspecified) 1
Hound - Basset 1
Maltese 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 3
Blindness 2
Glaucoma 2
Eye disorder NOS (for photophobia see 'neurological') 2
Lack of efficacy - NOS 2
Diarrhoea 2
Other abnormal test result NOS 2
Vomiting 2
Elevated alanine aminotransferase (ALT) 2
Elevated serum alkaline phosphatase (SAP) 2
Ocular discharge 1
Eyelid oedema 1

Outcome Breakdown

Ongoing
6 (54.5%)
Recovered/Normal
4 (36.4%)
Recovered with Sequela
1 (9.1%)

Dorzolamide Hcl Adverse Event Insights

11 reports name Dorzolamide Hcl; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Dorzolamide Hcl. Administration routes: Unknown, Ophthalmic, Intraocular.

By species: Dog (10 reports), Cat (1 reports). By breed: Pinscher - Miniature (1), Terrier - Jack Russell (1), Terrier - Boston (1).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (3), Blindness (2), Glaucoma (2), Eye disorder NOS (for photophobia see 'neurological') (2). Outcome, 11 coded reports: Ongoing leads at 54.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.